Valuation : CSL Limited

Market Cap 59.87B 51.48B 48.42B 44.2B 82.67B 5,662B 82.94B 574B 222B 2,899B 225B 220B 9,235B P/E 2027 *
20.5x
P/E 2028 * 18.6x
Enterprise Value 68.8B 59.17B 55.65B 50.8B 95.01B 6,507B 95.31B 660B 255B 3,332B 258B 253B 10,613B EV / Sales 2027 *
4.36x
EV / Sales 2028 * 4.19x
Free-Float
99.97%
Yield 2027 *
2.4%
Yield 2028 * 2.55%
1 day+0.94%
1 week+1.45%
Current month+1.88%
1 month+29.99%
3 months+75.73%
6 months+22.91%
Current year+1.25%
1 week 171.32
Extreme 171.32
177.39
1 month 131.85
Extreme 131.85
177.39
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
222.47
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap. Importance
8/26/26 Free

Director

523 0.0001%
8/26/26 Free 317 0.0001% -
8/26/26 Free

Director

1,586 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+0.94%+1.45%-18.08%-35.46% 59.87B
-1.87%+3.58%+44.36%+0.30% 82.65B
-2.23%+3.71%+478.96%+34.33% 58.11B
+1.31%-3.43%-7.43%+31.70% 50.35B
-0.43%-4.16%-0.48%+153.76% 46.62B
-1.64%+1.93%+56.98%-15.50% 32.63B
-0.98%+2.86%+46.30%+99.76% 25.69B
-0.89%-1.18%-0.10%+162.14% 22.49B
+0.84%-0.74%+64.49%+109.22% 16.33B
-0.87%-6.99%-21.81%+774.82% 14.79B
Average -0.59%+0.04%+64.32%+131.51% 40.95B
Weighted average by Cap. -0.69%+0.96%+82.53%+67.42%

Financials

2027 *2028 *
Net sales 15.76B 13.56B 12.75B 11.64B 21.77B 1,491B 21.84B 151B 58.43B 763B 59.19B 57.9B 2,432B 16.31B 14.03B 13.19B 12.04B 22.52B 1,543B 22.6B 156B 60.46B 790B 61.25B 59.91B 2,516B
Net income 2.84B 2.44B 2.29B 2.09B 3.92B 268B 3.93B 27.21B 10.52B 137B 10.65B 10.42B 438B 3.17B 2.72B 2.56B 2.34B 4.37B 299B 4.39B 30.36B 11.74B 153B 11.89B 11.63B 488B
Net Debt 8.93B 7.68B 7.23B 6.6B 12.34B 845B 12.38B 85.67B 33.11B 433B 33.55B 32.81B 1,378B 8.46B 7.28B 6.85B 6.25B 11.69B 801B 11.73B 81.18B 31.38B 410B 31.79B 31.09B 1,306B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
26-09-08 A$174.80 +0.94% 954,984
26-09-07 A$173.18 -0.76% 721,894
26-09-04 A$174.50 -0.57% 1,074,568
26-09-03 A$175.50 +0.95% 1,150,239
26-09-02 A$173.85 +0.89% 722,041
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
125.00USD
Average target price
122.30USD
Spread / Average Target
-2.16%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!